Active Filter(s):
Details:
The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Biophytis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 18, 2023